Group 1 - Baidu Group reported Q4 2025 total revenue of RMB 32.7 billion (USD 4.68 billion), a 5% quarter-on-quarter increase, driven by growth in core AI new business [1] - Operating profit for Q4 was RMB 1.5 billion (USD 0.21 billion) with an operating profit margin of 5%, while non-GAAP operating profit was RMB 3 billion (USD 0.42 billion) with a margin of 9% [1] - Net profit attributable to Baidu was RMB 1.8 billion (USD 0.25 billion), with a net profit margin of 5% and diluted earnings per ADS of RMB 3.71 (USD 0.53) [1] Group 2 - For the fiscal year 2025, total revenue reached RMB 129.1 billion (USD 18.46 billion), with operating profit (excluding long-term asset impairment) at RMB 10.4 billion (USD 1.48 billion) [2] - Non-GAAP net profit for the year was RMB 18.9 billion (USD 2.71 billion), with a non-GAAP net profit margin of 15% and diluted earnings per ADS of RMB 53.41 (USD 7.64) [2] - Smart cloud infrastructure revenue for Q4 was RMB 5.8 billion, with AI high-performance computing subscription revenue growing 143% year-on-year [2] Group 3 - In Q4 2025, Baidu's autonomous vehicle service, Apollo Go, achieved 3.4 million fully autonomous driving orders, with a total order volume growing over 200% year-on-year [3] - Apollo Go is expanding globally, with pilot projects in the UK, Switzerland, and the Middle East, including partnerships with Uber and Lyft [3] - AI-native marketing service revenue reached RMB 2.7 billion, a 110% year-on-year increase, while Baidu APP's monthly active users remained stable at 679 million [3] Group 4 - 2025 is identified as a pivotal year for AI becoming the new core of Baidu, with strong growth in smart cloud infrastructure and recognition of the company's end-to-end AI capabilities [4] - Baidu's core AI new business revenue exceeded RMB 11 billion in Q4, accounting for 43% of general business revenue, with a 6% quarter-on-quarter growth in general business revenue [4] - The company announced a new share buyback plan with an authorization amount of up to USD 5 billion and plans to initiate a dividend policy by the end of 2026 [4]

格隆汇2月26日丨蔚来-SW(09866.HK)宣布，董事会将于2026年3月10日(星期二)(北京╱香港╱新加坡时 间)举行董事会会议，以(其中包括)批准公司截至2025年12月31日止三个月及全年的未经审计财务业绩 ("第四季度及2025财年业绩")。公司将于2026年3月10日(星期二)(北京╱香港╱新加坡时间)在香港联交 所网站及公司网站上刊发其第四季度及2025财年业绩。 ...

格隆汇2月26日丨亨利加集团(03638.HK)发布公告，2026年2月26日耗资29.82万港元回购2.40万股，回购 价格每股12.3-12.5港元。 ...

智通财经APP讯，亨利加集团(03638)发布公告，于2026年2月26日斥资29.82万港元回购2.4万股。 （原标题：亨利加集团(03638)2月26日斥资29.82万港元回购2.4万股） ...

蔚来-SW(09866)发布公告，于2026年2月26日-全球智能电动汽车市场的先驱及领跑者蔚来集团(纽交 所：NIO;港交所：09866;新交所：NIO)宣布，公司及公司的子公司GeniTech Co.,Ltd.(神玑)与若干中国 投资者(神玑投资者)订立最终协议，据此，神玑投资者将以现金合共22.57亿元人民币认购神玑新发行股 份(投资交易)。神玑主要负责蔚来的智能驾驶芯片相关业务。投资交易须待达成惯常交割条件。待投资 交易完成后，蔚来一家子公司将继续持有神玑62.7%的控股权，而蔚来会继续将其财务业绩合并入账。 神玑投资者将合共持有神玑27.3%的股权。若干为管理神玑股份激励计划而持有股份的实体将合共持有 神玑余下10.0%的股权。 蔚来集团是全球智能电动汽车市场的先驱及领跑者。成立于2014年11月，蔚来致力于共创可持续和更美 好的未来，实现"Blue Sky Coming"的使命。蔚来的愿景是成为技术与体验领先的用户企业。蔚来设 计、开发、制造及销售智能电动汽车，推动新一代核心技术的创新。蔚来通过持续的技术突破及创新、 极致的产品及服务，和共同成长的社区使自己脱颖而出。公司旗下的蔚来品牌专注于高端智 ...

蔚来集团是全球智能电动汽车市场的先驱及领跑者。成立于2014年11月，蔚来致力于共创可持续和更美 好的未来，实现"Blue Sky Coming"的使命。蔚来的愿景是成为技术与体验领先的用户企业。蔚来设 计、开发、制造及销售智能电动汽车，推动新一代核心技术的创新。蔚来通过持续的技术突破及创新、 极致的产品及服务，和共同成长的社区使自己脱颖而出。公司旗下的蔚来品牌专注于高端智能电动汽 车，乐道品牌聚焦于家庭智能电动汽车，萤火虫品牌提供智能电动高端小车。 智通财经APP讯，蔚来-SW(09866)发布公告，于2026年2月26日 - 全球智能电动汽车市场的先驱及领跑 者蔚来集团(纽交所： NIO;港交所：09866;新交所：NIO)宣布，公司及公司的子公司GeniTech Co., Ltd. (神玑)与若干中国投资者(神玑投资者)订立最终协议，据此，神玑投资者将以现金合共22.57亿元人民币 认购神玑新发行股份(投资交易)。神玑主要负责蔚来的智能驾驶芯片相关业务。投资交易须待达成惯常 交割条件。待投资交易完成后，蔚来一家子公司将继续持有神玑62.7%的控股权，而蔚来会继续将其财 务业绩合并入账。神玑投资者将合共持 ...

花旗发布研报称，中电控股(00002)2025年盈利同比下跌10.8%至104.68亿元，较市场预期低6%。撇除一 次性项目，未计公允值变动前的经营盈利同比下跌2.4%至106.85亿元。另外，全年股息同比增加1.6%至 3.2港元，其中第四季股息为1.31港元，同比增加4%。该行目前予目标价76港元及"买入"评级。 该行认为，期内香港业务营运稳健，盈利同比增长7.3%至95.44亿元，占总盈利91%，占比同比上升15 个百分点。不过，澳洲业务经营盈利大幅下跌85.6%至8,500万元，主要受零售市场压力及转型成本影 响，未能被发电及灵活产能收益所抵消。而中国业务盈利则同比下跌13.7%至15.98亿元，新增可再生能 源产能的收益，被核电因市场电价下跌导致的较低贡献所抵消。 ...

亨利加集团(03638)发布公告，于2026年2月26日斥资29.82万港元回购2.4万股。 ...

Core Viewpoint - Lin Qingxuan's stock price has fallen below its initial offering price, indicating a decline in market confidence since its listing on the Hong Kong Stock Exchange on December 30, 2025 [1] Group 1: Stock Performance - Lin Qingxuan's stock closed at HKD 68.55, reflecting a decline of 6.735% [1] - The stock price has dropped below the initial offering price of HKD 77.77 [1] Group 2: IPO Details - Lin Qingxuan issued a total of 13,966,450 H-shares, with 1,396,650 shares available for Hong Kong and 12,569,800 shares for international investors [1] - The total amount raised from the IPO was HKD 1,086.2 million, with net proceeds of HKD 997.1 million after deducting estimated listing expenses of HKD 89.1 million [1] Group 3: Key Investors - Notable cornerstone investors include Fidelity International (Hong Kong) Limited, Mega Prime Development Limited, Zhengxin Valley Capital, Duckling Fund, L.P., SynerSuccess Capital Ltd., Dajia Insurance Group, and Yield Royal Investment Holding [1]

Core Viewpoint - Mirxes has signed a memorandum of understanding with Apollo Health and Lifestyle to jointly develop and commercialize advanced cancer early screening solutions in India and surrounding countries, planning to establish a joint venture valued at no less than $50 million [1][6]. Group 1: Market Opportunity and Strategic Moves - The global tumor early screening market is projected to grow at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2028, making this strategic partnership a crucial step for Mirxes to enhance its competitiveness and break regional limitations [1]. - Mirxes recently completed the enrollment of 6,000 participants in the largest colorectal cancer blood early screening clinical trial in Southeast Asia, marking a significant milestone for the company [2]. - The company raised approximately HKD 700 million in February, with 20% allocated for expanding into emerging markets like India, creating a strong foundation for its market penetration efforts [2][6]. Group 2: Technological and Product Development - The collaboration with Apollo opens up the rapidly growing healthcare market in India, where cancer incidence is high, with a lifetime risk of 11% for cancer [3]. - Mirxes' colorectal cancer early screening product has shown over 80% sensitivity and about 90% specificity, tailored for the Asian population, significantly enhancing its market adaptability [3][7]. - The product pipeline includes a gastric cancer early screening product, which is the first approved IVD product for gastric cancer, expected to generate stable cash flow starting in 2025 [4]. Group 3: Competitive Advantage and Market Positioning - Mirxes has established a strong technical barrier and a rich product pipeline, with its core technology in miRNA being a key differentiator in the liquid biopsy field [7]. - The partnership with Apollo allows Mirxes to leverage Apollo's extensive healthcare network to accelerate commercialization and optimize product parameters for the Indian population [8]. - The collaboration is expected to extend into preventive medicine, broadening Mirxes' business scope beyond cancer screening [8]. Group 4: Response to Public Health Needs - The partnership coincides with public health challenges in India, such as the Nipah virus outbreak, highlighting the urgent need for rapid and convenient home testing solutions [11]. - Mirxes' technology platform can be adapted for infectious disease rapid testing, addressing public health emergencies while also entering the consumer health testing market [11]. Group 5: Financial and Market Dynamics - The establishment of the joint venture is not merely conceptual but involves real funding, technology licensing, and synchronized commercialization efforts, providing a clear valuation anchor for Mirxes' Indian operations [12]. - The current stock price reflects previous liquidity pressures and conservative market expectations, with the partnership expected to drive value release through commercialization and globalization [12].